Molecular Residual Disease Using ctDNA May Predict Benefit From Consolidation Immunotherapy in NSCLC

NEW YORK − A retrospective study published in Nature Cancer last week found that circulating tumor DNA can be used to identify non-small cell lung cancer patients who might benefit from consolidation therapy with immune checkpoint inhibitors (ICI) after chemoradiation and to monitor their responses.